spacer
home > pmps > winter 2002 > are you available?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Are You Available?

Competition in the pharmaceutical industry has intensified over the past 12 months. Now more than ever companies must minimise IT downtime to stay ahead of the competition. This article explores the components of a global business availability programme.

For many years the pharmaceutical industry has had to ensure that buildings, facilities, data and employees are protected from everyday threats and more calculated sabotage risks. And as an industry, it is one of the leading examples of best practice for business continuity. But as global trading barriers have fallen and the 24-hour consumer and business society raises service expectations and demands, so the industry must reinvent its business continuity processes and adopt a web of contingency plans to protect disparate operations across the world.

Over the past 18 months, business continuity (BC) - the ability to keep business systems and processes operating at all times - has grabbed headlines. At home and abroad a number of incidents have increased awareness of BC, provoked government warnings, guidelines and new legislation across the globe. As a result, many organisations should have set the wheels in motion to review business continuity programmes.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Russell Flower, Strategy Director at Synstar
Russell Flower joined Synstar in 1993. He holds the newly created role of Strategy Director to assist Synstar in determining a short- to medium-term strategy to achieve corporate growth and enter new markets and service areas.

The role also covers developing the necessary marketing collateral, presentation material and cost models to fully enable successful business development of these strategies. This will ensure that each strategy is turned from thought into a delivered Synstar service across the pan-European network. Russell is based at Bracknell, in the UK.

spacer
Russell Flower
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TAGRISSOTM (osimertinib) DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATMENT OF STAGE IB-IIIA COMPLETELY RESECTED PATIENTS WITH EGFR MUTATION

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement